Zogenix and Valeant Pharmaceuticals Enter Exclusive Co-Promotion Agreement for Migranal(R) Nasal Spray

Zogenix and Valeant Pharmaceuticals Enter Exclusive Co-Promotion Agreement for
Migranal(R) Nasal Spray

Zogenix Sales Force to Begin Promoting Migranal(R) to Its Customer Base of
Neurologists and Headache Specialists

SAN DIEGO, June 27, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a
pharmaceutical company commercializing and developing products for the
treatment of central nervous system disorders and pain, announced today an
exclusive co-promotion agreement for Migranal® (dihydroergotamine mesylate,
USP) Nasal Spray in the United States.

Under the terms of the agreement, Zogenix's sales force will begin selling
Migranal Nasal Spray to its customer base of prescribers, which is primarily
composed of neurologists, headache specialists and related nurse practitioners
and physician assistants in late July 2013. The initial term of the agreement
will be through December 31, 2015, and can be extended by mutual agreement of
the parties. Valeant will record all product revenues and Zogenix will be
compensated in the form of a quarterly service fee that is calculated as a
percentage of net sales over a baseline amount.

Migranal Nasal Spray is indicated for the acute treatment of migraine
headaches with or without aura. It is complementary to Zogenix's
commercialized migraine product, SUMAVEL® DosePro® Needle-free Delivery System
(sumatriptan injection), which is indicated for the acute treatment of
migraine attacks, with or without aura, and cluster headache. Because the
active ingredients in Migranal Nasal Spray and SUMAVEL DosePro are from
different classes of migraine prescription medications, Migranal may allow
patients to get relief from attacks if they have not responded to triptans,
the most widely prescribed class of migraine treatments.

Roger L. Hawley, chief executive officer of Zogenix, stated, "We are pleased
to enter a co-promotion agreement with Valeant for Migranal Nasal Spray. We
view Migranal as complementary to SUMAVEL DosePro and supportive of the
migraine treatment guidelines, which encourage the use of a toolbox of
treatment options to address the variety in migraine attacks. We believe that
our sales force is well positioned to expand adoption of Migranal with
neurologists and headache specialists that prescribe SUMAVEL DosePro,
providing more patients with this treatment option. We believe this agreement
fits well with our vision to be the leading specialty migraine company and
help drive our commercial operations towards profitability."

About SUMAVEL DosePro

SUMAVEL DosePro (sumatriptan injection) is indicated for the acute treatment
of migraine attacks, with or without aura, and the acute treatment of cluster
headache episodes. SUMAVEL DosePro should only be used where a clear diagnosis
of migraine or cluster headache has been established. SUMAVEL DosePro is not
intended for the prophylactic therapy of migraine or for use in the management
of hemiplegic or basilar migraine and should not be administered
intravenously. For a given attack, if a patient does not respond to the first
dose of SUMAVEL DosePro, the diagnosis of migraine or cluster headache should
be reconsidered before administration of a second dose.

Important Safety Information

SUMAVEL DosePro is contraindicated in patients with uncontrolled hypertension,
in patients with history, symptoms or signs of ischemic heart disease,
coronary artery vasospasm, cerebrovascular or peripheral vascular disease
including ischemic bowel disease and in patients with other significant
underlying cardiovascular diseases or known hypersensitivity to sumatriptan.
SUMAVEL DosePro should not be given to patients in whom unrecognized coronary
artery disease is predicted by the presence of risk factors without a prior
cardiovascular evaluation.

Serious cardiovascular events, including death, have been reported when taking
sumatriptan, including patients with no findings of cardiovascular disease.
Considering the extent of use of sumatriptan in patients with migraine, the
incidence of these events is extremely low. Cerebrovascular events, some
fatal, have been reported in patients treated with sumatriptan. In a number of
cases, it appears possible that the cerebrovascular events were primary,
sumatriptan having been administered in the incorrect belief the symptoms
experienced were a consequence of migraine when they were not. It is important
to advise patients not to administer SUMAVEL DosePro if a headache being
experienced is atypical.

Do not use Sumavel DosePro and any ergotamine-containing or ergot-type
medication within 24 hours of each other; do not use SUMAVEL DosePro and
another 5-HT[1] agonist (e.g. triptan) within 24 hours of each other (with the
exception of a single dose of another sumatriptan product, provided the doses
are separated by at least 1 hour). SUMAVEL DosePro is not generally
recommended for use with MAO-A inhibitors. The development of a potentially
life-threatening serotonin syndrome may occur with triptans, including
treatment with SUMAVEL DosePro, particularly during combined use with
selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine
reuptake inhibitors (SNRIs). SUMAVEL DosePro should be used during pregnancy
only if the potential benefit justifies the potential risk.

In controlled clinical trials with sumatriptan injection, the most common
adverse reactions were injection site reactions, tingling, warm/hot sensation,
burning sensation, feeling of heaviness, pressure sensation, feeling of
tightness, numbness, feeling strange, tight feeling in head, flushing,
tightness in chest, discomfort in nasal cavity/sinuses, jaw discomfort,
dizziness/vertigo, drowsiness/sedation and headache.

For full prescribing information, please click here:

For more information about SUMAVEL DosePro, please visit


Serious and/or life-threatening peripheral ischemia has been associated with
the coadministration of dihydroergotamine with potent CYP3A4 inhibitors
including protease inhibitors and macrolide antibiotics. Because CYP3A4
inhibition elevates the serum levels of dihydroergotamine, the risk for
vasospasm leading to cerebral ischemia and/or ischemia of the extremities is
increased. Hence, concomitant use of these medications is contraindicated.

  oMigranal Nasal Spray should not be given to patients with ischemic heart
    disease (angina pectoris, history of myocardial infarction, or documented
    silent ischemia), to patients who have clinical symptoms or findings
    consistent with coronary artery vasospasm, including Prinzmetal's variant
  oMigranal also should not be given to patients with uncontrolled
    hypertension, patients who have used 5-HT1 agonists, ergotamine-containing
    or ergot-type medications or methysergide within the last 24 hours, or
    patients with hemiplegic or basilar migraine.
  oMigranal Nasal Spray is also contraindicated in patients with known
    peripheral arterial disease, sepsis, following vascular surgery, and
    severely impaired hepatic or renal function.
  oMigranal Nasal Spray should not be administered to pregnant women or
    nursing mothers.

Migranal^® Nasal Spray should only be used where a clear diagnosis of migraine
headache has been established.

Serious cardiac events, including some that have been fatal, have occurred
following use of DHE 45 but are extremely rare. During clinical studies and
the foreign postmarketing experience with Migranal Nasal Spray, there have
been no fatalities due to cardiac events. The most commonly reported adverse
events in clinical trials for Migranal Nasal Spray were rhinitis, altered
sense of taste, application site reactions, dizziness, nausea and vomiting.
Adverse events associated with discontinuation were rhinitis, dizziness,
facial edema, cold sweats, accidental trauma, depression, elective surgery,
somnolence, allergy, vomiting, hypotension, and paresthesia.

For more information on Migranal, visit http://migranal.com/migranal-home.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville,
California, is a pharmaceutical company commercializing and developing
products for the treatment of central nervous system disorders and pain.
Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection)
Needle-free Delivery System, was launched in January 2010 for the acute
treatment of migraine and cluster headache. Zogenix's lead investigational
product candidate, Zohydro™ ER (hydrocodone bitartrate extended release
capsules), is an oral, extended-release formulation of various strengths of
hydrocodone, without acetaminophen, intended for administration every 12 hours
for around the clock management of moderate to severe chronic pain. In May
2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER.
Zogenix's second investigational product candidate, Relday™, is a proprietary,
long-acting injectable formulation of risperidone for the treatment of
schizophrenia; an investigational new drug application was submitted to the
FDA in May 2012.

Forward-Looking Statements

Zogenix cautions you that statements included in this press release that are
not a description of historical facts are forward-looking statements. Words
such as "believes," "anticipates," "plans," "expects," "indicates," "will,"
"intends," "potential," "suggests," "assuming" and similar expressions are
intended to identify forward-looking statements. These forward-looking
statements include statements regarding Migranal Nasal Spray's and SUMAVEL
DosePro's usefulness as a therapeutic option in relieving migraine pain and
symptoms, the potential for the co-promotion arrangement to increase sales of
Migranal Nasal Spray and the potential for the co-promotion arrangement to
help Zogenix achieve profitability. The inclusion of forward-looking
statements should not be regarded as a representation by Zogenix that any of
its plans will be achieved. Actual results may differ from those set forth in
this release due to the risk and uncertainties inherent in Zogenix's business,
including, without limitation: Zogenix's ability to successfully sell Migranal
Nasal Spray to Zogenix's customer base of prescribers; unexpected adverse side
effects relating to Migranal Nasal Spray that could result in recalls or
product liability claims; the potential early termination of the co-promote
arrangement; and other risks described in the company's prior press releases
and filings with the Securities and Exchange Commission.

You are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof, and Zogenix undertakes no
obligation to revise or update this release to reflect events or circumstances
after the date hereof. All forward-looking statements are qualified in their
entirety by this cautionary statement. This caution is made under the safe
harbor provisions of Section 21E of the Private Securities Litigation Reform
Act of 1995.

SUMAVEL^®, DosePro^®, Relday^TM and Zohydro^TM ER are trademarks of Zogenix,

MIGRANAL® is a registered trademark of Valeant Pharmaceuticals International,
Inc. or its affiliates.


CONTACT: Zogenix Contacts:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com
         Caitlin Cox | The Ruth Group
         646.536.7033 | ccox@theruthgroup.com
Press spacebar to pause and continue. Press esc to stop.